Trump says he’s ‘strongly’ considering reclassifying pot via executive order

Trump says he’s ‘strongly’ considering reclassifying pot via executive order


Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on U.S. President Joe Biden “to take action on cannabis clemency before the November general election” October 24, 2022 in Washington, DC.

Win Mcnamee | Getty Images

Pot stocks failed to light up for a second day on Monday even after President Donald Trump confirmed he’s considering an executive order loosening regulations on marijuana.

The Amplify Seymour Cannabis ETF (CNBS) took a leg up in afternoon trading after Trump said he was weighing reclassifying the drug. Still, the fund was down nearly 7% with investors taking profits following a surge of more than 50% on Friday.

When asked Monday if he was looking at an executive order on rescheduling weed, Trump responded “We are considering that.”

“A lot of people want to see it the reclassification, because it leads to tremendous amounts of research that can’t be done unless you reclassify,” he said. “So we are looking at that very strongly.”

Trump’s comment comes after reports on Friday said the president was thinking about instructing federal agencies to reclassify marijuana as a less-regulated Schedule III drug from a Schedule I substance. A person familiar with the matter told CNBC an order from the White House could come as soon as Monday.

The reports ignited a rally in the sector on Friday that drove the Amplify Seymour fund to its best day on record. The ETF swung into positive territory for the year, putting it on track to snap a four-year losing streak.

Industry insiders have long expected this change in classification, which would move cannabis out of a group of drugs that includes heroin to a cohort alongside steroids and Tylenol with codeine. Trump floated a change in marijuana’s classification in August.

But they said there’s more optimism that enough momentum exists to get such a move — which could help warm up banks and big investors to the sector — across the finish line.

“I’m a lot more optimistic than I ever have been,” Tilray CEO Irwin Simon told CNBC on Friday.

Weed producers Tilray Brands and Canopy Growth slid 10% and 4.6%, respectively, in Monday’s session. Retailer SNDL tumbled more than 13%.

— CNBC’s Kevin Breuninger and Brandon Gomez contributed reporting.

Get Morning Squawk directly to your inbox



Source

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Health

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever.  2026 is likely the year that two new oral weight loss […]

Read More
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off
Health

Pfizer’s modest 2026 outlook shows its big investments will take time to pay off

Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs. Those hurdles aren’t surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales […]

Read More
Why Wall Street and Jim Cramer think Danaher stock is ‘ready to go for a romp’
Health

Why Wall Street and Jim Cramer think Danaher stock is ‘ready to go for a romp’

Danaher is finally turning the corner. CNBC’s Jim Cramer sees it. Wall Street does, too. The life sciences stock is “ready to go for a romp” after years of “nightmare” performance, Cramer said during Friday’s December Monthly Meeting for Investing Club members. Danaher — which makes tools and technologies used by pharmaceutical, biotech, and medical […]

Read More